The Biostatistics and Computing Core for the Duke SPORE in Breast Cancer is intended to expedite planning and conduct of translational research. This Core will be developed in combination with the Institute of Statistics and Decision Sciences and the Duke Tumor Registry. The Biostatistics and Computing Core will not duplicate existing resources but will enhance Tumor Registry resources for the purposes of this SPORE. Dr. Donald Berry, Professor of the Institute of Statistics and Decision Sciences and statistician for the Cancer and leukemia Group B (CALGB) Breast Cancer Committee, and Dr. Carey Floyd, Associate Professor of Radiology and Biomedical Engineering and is Co-Director of the Duke Tumor Registry, will be managers of this Core. The remaining staff for this Core will include one additional statistician, Constance Cirrincione, who is the staff statistician on the CALGB Breast Cancer Committee. This Core will provide assistance in the statistical aspects of design, conduct, and analysis of basic and clinical scientific studies. Projects involving clinical research will make use of this Core to facilitate efficient clinical trial conduct, proper quality assurance, and timely evaluation and reporting of data. A computerized database using INGRES software will be run on a VAX 4500 with linkage to VT100 terminals or personal computers outfitted with Kermit or Procomm software. A generic set of breast cancer forms has been created, with monthly entry of data into the computerized data base. In addition, individual data entry screens will be developed for specific projects. The data system has automated error checking features, and incorporates standard data security features. Reports on demographics, toxicity, dose intensity, and response can be generated. Data can be transferred into the SAS/stat database for statistical analysis. This Core will also coordinate quality control efforts for the SPORE clinical trials. Monthly clinical trial reports will be circulated to investigators, and will be reviewed at the monthly Core meetings. Six- month summaries of these reports will be reviewed at the biannual review sessions. Annual audits of ongoing clinical trials will be performed by a team consisting of the Core statistician, Dr. Berry, the Principal Investigator of the SPORE, Dr. Iglehart, and one member of the Advisory Board. In addition, this Core will be a resource for the quantitative but non-clinical-trial aspects of the SPORE. This includes aiding in the use of models for assessing the level of genetic susceptibility in Project 3 and assessing the utility of surrogate markers for chemoprevention in Project l.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA068438-02
Application #
5209489
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost
Osada, Takuya; Hartman, Zachary C; Wei, Junping et al. (2018) Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. Breast Cancer Res 20:90
Goncalves, Rodrigo; DeSchryver, Katherine; Ma, Cynthia et al. (2017) Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer. Breast Cancer Res Treat 165:355-364
Mertins, Philipp; Yang, Feng; Liu, Tao et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13:1690-704
Li, Shunqiang; Shen, Dong; Shao, Jieya et al. (2013) Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 4:1116-30
Cao, Yiting; Eble, Joseph M; Moon, Ejung et al. (2013) Tumor cells upregulate normoxic HIF-1? in response to doxorubicin. Cancer Res 73:6230-42
Ellis, Matthew J; Ding, Li; Shen, Dong et al. (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486:353-60
D'Amato, Nicholas C; Ostrander, Julie H; Bowie, Michelle L et al. (2012) Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system. PLoS One 7:e45684
Aird, Katherine M; Allensworth, Jennifer L; Batinic-Haberle, Ines et al. (2012) ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. Breast Cancer Res Treat 132:109-19
Il'yasova, Dora; Kennedy, Kelly; Spasojevic, Ivan et al. (2011) Individual responses to chemotherapy-induced oxidative stress. Breast Cancer Res Treat 125:583-9
Ye, Xiaodong; Fels, Diane; Tovmasyan, Artak et al. (2011) Cytotoxic effects of Mn(III) N-alkylpyridylporphyrins in the presence of cellular reductant, ascorbate. Free Radic Res 45:1289-306

Showing the most recent 10 out of 103 publications